CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Cardiff Oncology, Inc. - CRDF CFD

1.6649
1.19%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.0602
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Cardiff Oncology Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.6849
Open* 1.6949
1-Year Change* -8.3%
Day's Range* 1.6549 - 1.6949
52 wk Range 0.94-2.79
Average Volume (10 days) 178.60K
Average Volume (3 months) 3.71M
Market Cap 65.23M
P/E Ratio -100.00K
Shares Outstanding 44.68M
Revenue 460.00K
EPS -0.91
Dividend (Yield %) N/A
Beta 1.68
Next Earnings Date Feb 29, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 20, 2024 1.6849 0.0100 0.60% 1.6749 1.7149 1.6449
Feb 16, 2024 1.7149 -0.0300 -1.72% 1.7449 1.7549 1.6949
Feb 15, 2024 1.6949 -0.0500 -2.87% 1.7449 1.7749 1.6749
Feb 14, 2024 1.7149 0.0300 1.78% 1.6849 1.7249 1.6349
Feb 13, 2024 1.6549 -0.0600 -3.50% 1.7149 1.7249 1.6049
Feb 12, 2024 1.7849 -0.0200 -1.11% 1.8049 1.8149 1.7349
Feb 9, 2024 1.7549 -0.0500 -2.77% 1.8049 1.8349 1.7249
Feb 8, 2024 1.7949 -0.0100 -0.55% 1.8049 1.8749 1.7649
Feb 7, 2024 1.8249 0.1200 7.04% 1.7049 1.8849 1.6949
Feb 6, 2024 1.7849 0.2400 15.53% 1.5449 1.8649 1.5449
Feb 5, 2024 1.4449 -0.0900 -5.86% 1.5349 1.5449 1.4349
Feb 2, 2024 1.5549 -0.0200 -1.27% 1.5749 1.5749 1.5049
Feb 1, 2024 1.5749 0.0100 0.64% 1.5649 1.6849 1.5649
Jan 31, 2024 1.5349 0.0100 0.66% 1.5249 1.5949 1.5249
Jan 30, 2024 1.5149 -0.0100 -0.66% 1.5249 1.5349 1.5149
Jan 29, 2024 1.5349 0.0700 4.78% 1.4649 1.5649 1.4649
Jan 26, 2024 1.4849 0.0200 1.37% 1.4649 1.4849 1.4349
Jan 25, 2024 1.4549 0.0000 0.00% 1.4549 1.4849 1.4349
Jan 24, 2024 1.4949 -0.0300 -1.97% 1.5249 1.5249 1.4349
Jan 23, 2024 1.5149 0.0400 2.71% 1.4749 1.5449 1.4649

Cardiff Oncology, Inc. Events

Time (UTC) Country Event
Thursday, February 29, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Cardiff Oncology Inc Earnings Release
Q4 2023 Cardiff Oncology Inc Earnings Release

Forecast

-

Previous

-
Thursday, May 2, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Cardiff Oncology Inc Earnings Release
Q1 2024 Cardiff Oncology Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0.386 0.359 0.36599 0.24463 0.37833
Revenue 0.386 0.359 0.36599 0.24463 0.37833
Cost of Revenue, Total 0 0.59746
Gross Profit 0.24463 -0.21913
Total Operating Expense 40.288 29.214 19.4519 16.9231 17.4138
Selling/General/Admin. Expenses, Total 13.181 11.838 8.21647 5.76089 8.00558
Research & Development 27.107 17.376 11.2354 11.1622 8.16401
Unusual Expense (Income) 0 0.64671
Operating Income -39.902 -28.855 -19.0859 -16.6785 -17.0354
Interest Income (Expense), Net Non-Operating 1.581 0.549 -0.19256 0.26236 0.81109
Other, Net -0.383 0.015 -0.02824 0.00198 -0.23683
Net Income Before Taxes -38.704 -28.291 -19.3067 -16.4142 -16.4612
Net Income After Taxes -38.704 -28.291 -19.3067 -16.4142 -16.4612
Net Income Before Extra. Items -38.704 -28.291 -19.3067 -16.4142 -16.4612
Net Income -38.704 -28.291 -19.3067 -16.4142 -16.4612
Total Adjustments to Net Income -0.024 -0.024 -3.29072 -0.29251 -2.79377
Income Available to Common Excl. Extra. Items -38.728 -28.315 -22.5974 -16.7067 -19.2549
Income Available to Common Incl. Extra. Items -38.728 -28.315 -22.5974 -16.7067 -19.2549
Dilution Adjustment
Diluted Net Income -38.728 -28.315 -22.5974 -16.7067 -19.2549
Diluted Weighted Average Shares 43.6 39.03 20.8747 5.97391 2.33018
Diluted EPS Excluding Extraordinary Items -0.88826 -0.72547 -1.08253 -2.79661 -8.26329
Diluted Normalized EPS -0.88826 -0.72547 -1.08253 -2.79661 -7.98575
Total Extraordinary Items
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.108 0.083 0.128 0.093 0.091
Revenue 0.108 0.083 0.128 0.093 0.091
Total Operating Expense 12.316 12.135 9.52 9.086 10.534
Selling/General/Admin. Expenses, Total 4.296 3.083 3.078 3.077 3.086
Research & Development 8.02 9.052 6.442 6.009 7.448
Operating Income -12.208 -12.052 -9.392 -8.993 -10.443
Interest Income (Expense), Net Non-Operating 1.053 0.94 0.74 0.458 0.253
Other, Net 0.005 -0.111 -0.045 -0.036 -0.253
Net Income Before Taxes -11.15 -11.223 -8.697 -8.571 -10.443
Net Income After Taxes -11.15 -11.223 -8.697 -8.571 -10.443
Net Income Before Extra. Items -11.15 -11.223 -8.697 -8.571 -10.443
Net Income -11.15 -11.223 -8.697 -8.571 -10.443
Total Adjustments to Net Income -0.006 -0.006 -0.006 -0.006 -0.006
Income Available to Common Excl. Extra. Items -11.156 -11.229 -8.703 -8.577 -10.449
Income Available to Common Incl. Extra. Items -11.156 -11.229 -8.703 -8.577 -10.449
Diluted Net Income -11.156 -11.229 -8.703 -8.577 -10.449
Diluted Weighted Average Shares 44.677 44.677 44.527 43.333 43.306
Diluted EPS Excluding Extraordinary Items -0.2497 -0.25134 -0.19545 -0.19793 -0.24128
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.2497 -0.25134 -0.19545 -0.19793 -0.24128
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 111.284 146.127 133.356 11.3537 12.7653
Cash and Short Term Investments 105.267 140.821 130.981 10.1953 11.4531
Cash & Equivalents 16.347 11.943 130.981 10.1953 11.4531
Short Term Investments 88.92 128.878
Total Receivables, Net 0.771 0.535 0.32046 0.20348 0.16776
Accounts Receivable - Trade, Net 0.771 0.535 0.32046 0.20348 0.16776
Prepaid Expenses 5.246 4.771 2.05532 0.95496 1.14438
Total Assets 116.191 149.544 134.727 13.0865 14.1725
Property/Plant/Equipment, Total - Net 3.52 3.178 0.9667 1.57524 1.30443
Property/Plant/Equipment, Total - Gross 6.933 6.619 3.97072 4.17953 3.41449
Accumulated Depreciation, Total -3.413 -3.441 -3.00403 -2.60429 -2.11006
Other Long Term Assets, Total 1.387 0.239 0.40423 0.15758 0.1028
Total Current Liabilities 7.808 6.559 6.11898 4.78174 2.92332
Accounts Payable 1.956 1.439 1.36601 0.6563 0.66484
Accrued Expenses 5.727 4.523 4.22897 3.69269 1.35082
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total 0.125 0.597 0.524 0.43276 0.90766
Total Liabilities 9.848 9.127 6.56951 5.7752 4.0883
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Other Liabilities, Total 2.04 2.568 0.45053 0.99346 1.16499
Total Equity 106.343 140.417 128.158 7.31134 10.0842
Redeemable Preferred Stock 1.044 0.606 0.606 0.606 0.606
Preferred Stock - Non Redeemable, Net -1.044 -0.605 -0.60528 -0.60594 -0.60594
Common Stock 0.004 0.004 0.00368 0.00831 0.00774
Additional Paid-In Capital 404.834 400.503 361.82 217.173 202.268
Retained Earnings (Accumulated Deficit) -298.1 -259.81 -231.495 -208.898 -192.191
Other Equity, Total -0.395 -0.281 -2.17126 -0.97167 0
Total Liabilities & Shareholders’ Equity 116.191 149.544 134.727 13.0865 14.1725
Total Common Shares Outstanding 44.677 41.964 36.7808 8.59363 3.83188
Total Preferred Shares Outstanding 0.0606 0.71564 0.0606 0.0606 0.0606
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 83.905 92.731 101.753 111.284 119.755
Cash and Short Term Investments 81.363 89.428 96.968 105.267 114.303
Cash & Equivalents 15.233 19.369 15.017 16.347 18.717
Short Term Investments 66.13 70.059 81.951 88.92 95.586
Total Receivables, Net 0.198 0.161 0.676 0.771 0.65
Accounts Receivable - Trade, Net 0.198 0.161 0.676 0.771 0.65
Prepaid Expenses 2.344 3.142 4.109 5.246 4.802
Total Assets 88.452 97.455 106.549 116.191 123.631
Property/Plant/Equipment, Total - Net 3.16 3.334 3.435 3.52 3.692
Property/Plant/Equipment, Total - Gross 6.824 6.891 6.894 6.933 7.021
Accumulated Depreciation, Total -3.664 -3.557 -3.459 -3.413 -3.329
Other Long Term Assets, Total 1.387 1.39 1.361 1.387 0.184
Total Current Liabilities 9.018 9.123 8.148 7.808 8.245
Accounts Payable 2.179 2.939 2.914 1.956 1.425
Accrued Expenses 6.714 6.059 5.109 5.727 6.255
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.125 0.125 0.125 0.125 0.565
Total Liabilities 10.625 10.876 10.046 9.848 10.419
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 1.607 1.753 1.898 2.04 2.174
Total Equity 77.827 86.579 96.503 106.343 113.212
Redeemable Preferred Stock 1.062 1.056 1.05 1.044 0.606
Common Stock 0.004 0.004 0.004 0.004 0.004
Additional Paid-In Capital 408.434 407.479 405.898 404.834 403.822
Retained Earnings (Accumulated Deficit) -330.204 -320.473 -309.323 -298.1 -289.835
Other Equity, Total -0.407 -0.431 -0.076 -0.395 -0.779
Total Liabilities & Shareholders’ Equity 88.452 97.455 106.549 116.191 123.631
Total Common Shares Outstanding 44.677 44.677 44.677 44.677 43.335
Total Preferred Shares Outstanding 0.0606 0.0606 0.0606 0.0606 0.38811
Preferred Stock - Non Redeemable, Net -1.062 -1.056 -1.05 -1.044 -0.606
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -38.704 -28.291 -19.3067 -16.4142 -16.4612
Cash From Operating Activities -33.82 -23.04 -16.315 -13.2675 -13.199
Cash From Operating Activities 0.236 0.451 0.46601 0.49423 0.85949
Non-Cash Items 5.028 6.589 3.18023 1.56008 2.09003
Cash Taxes Paid 0.002 0.001 0.0008 0.0008 0.0008
Cash Interest Paid 0 0.02248
Changes in Working Capital -0.38 -1.789 -0.65453 1.09235 0.31265
Cash From Investing Activities 38.149 -131.448 -0.21188 -0.06762 0.02284
Capital Expenditures -1.006 -0.205 -0.21188 -0.06762 -0.0051
Other Investing Cash Flow Items, Total 39.155 -131.243 0 0.02794
Cash From Financing Activities 0.075 35.45 137.312 12.0773 16.4035
Issuance (Retirement) of Stock, Net 0.075 35.45 137.32 12.1173 19.6127
Issuance (Retirement) of Debt, Net 0 0 0 -1.37541
Foreign Exchange Effects 0
Net Change in Cash 4.404 -119.038 120.785 -1.25784 3.22737
Financing Cash Flow Items 0 -0.0075 -0.04 -1.83374
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -11.223 -38.704 -30.007 -21.436 -10.993
Cash From Operating Activities -8.659 -33.82 -24.43 -16.944 -10.249
Cash From Operating Activities 0.09 0.236 0.15 0.069 0.031
Non-Cash Items 0.901 5.028 4.055 2.903 1.637
Cash Taxes Paid 0 0.002 0.001 0.001 0.001
Changes in Working Capital 1.573 -0.38 1.372 1.52 -0.924
Cash From Investing Activities 7.329 38.149 31.129 25.966 18.358
Other Investing Cash Flow Items, Total 7.337 39.155 32.06 26.449 18.529
Cash From Financing Activities 0 0.075 0.075 0 0
Issuance (Retirement) of Stock, Net 0.075 0.075 0 0
Net Change in Cash -1.33 4.404 6.774 9.022 8.109
Financing Cash Flow Items 0
Issuance (Retirement) of Debt, Net
Capital Expenditures -0.008 -1.006 -0.931 -0.483 -0.171
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Pfizer Inc Corporation 5.3978 2411575 0 2023-04-24 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.3488 1942918 0 2023-06-30 LOW
Acorn Bioventures L.P. Venture Capital 2.9803 1331507 0 2022-12-31 HIGH
Caxton Associates LP Hedge Fund 2.2016 983607 983607 2022-12-31 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.685 752813 2454 2023-06-30 LOW
Laurion Capital Management LP Hedge Fund 1.6163 722100 0 2023-06-30 HIGH
Pace (Gary William) Individual Investor 1.4433 644811 0 2023-04-24 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.8531 381150 -32352 2023-06-30 LOW
Renaissance Technologies LLC Hedge Fund 0.6968 311290 -20018 2023-06-30 HIGH
GSA Capital Partners LLP Hedge Fund 0.664 296677 15998 2023-06-30 HIGH
Two Sigma Investments, LP Hedge Fund 0.5955 266032 92532 2023-06-30 HIGH
Assenagon Asset Management S.A. Investment Advisor 0.3188 142428 -252566 2023-06-30 HIGH
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.3132 139945 0 2023-06-30 LOW
William Blair & Company, L.L.C. (Research) Research Firm 0.2921 130500 0 2023-06-30 LOW
ACT Capital Management, L.L.C. Hedge Fund 0.2699 120600 0 2022-09-30 MED
White (Lale) Individual Investor 0.2547 113788 43858 2023-04-24
Abaris Investment Management AG Investment Advisor 0.2364 105600 0 2023-04-30 MED
Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 0.2172 97053 55576 2023-06-30 MED
Susquehanna International Group, LLP Investment Advisor 0.2115 94504 -97999 2023-06-30 MED
Citadel Advisors LLC Hedge Fund 0.1928 86123 79116 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Cardiff Oncology, Inc. Company profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company''s onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Industry: Biotechnology & Medical Research (NEC)

11055 Flintkote Ave
SAN DIEGO
CALIFORNIA 92121
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

BTC/USD

51,105.50 Price
-1.950% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

XRP/USD

0.54 Price
-4.410% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Gold

2,022.64 Price
-0.080% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

17,400.00 Price
-0.670% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading